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ABSTRACT: TGF-β1, -β2, and -β3 are small, secreted
signaling proteins. They share 71−80% sequence identity
and signal through the same receptors, yet the isoform-specific
null mice have distinctive phenotypes and are inviable. The
replacement of the coding sequence of TGF-β1 with TGF-β3
and TGF-β3 with TGF-β1 led to only partial rescue of the
mutant phenotypes, suggesting that intrinsic differences
between them contribute to the requirement of each in vivo.
Here, we investigated whether the previously reported
differences in the flexibility of the interfacial helix and
arrangement of monomers was responsible for the differences in activity by generating two chimeric proteins in which residues
54−75 in the homodimer interface were swapped. Structural analysis of these using NMR and functional analysis using a dermal
fibroblast migration assay showed that swapping the interfacial region swapped both the conformational preferences and activity.
Conformational and activity differences were also observed between TGF-β3 and a variant with four helix-stabilizing residues
from TGF-β1, suggesting that the observed changes were due to increased helical stability and the altered conformation, as
proposed. Surface plasmon resonance analysis showed that TGF-β1, TGF-β3, and variants bound the type II signaling receptor,
TβRII, nearly identically, but had small differences in the dissociation rate constant for recruitment of the type I signaling
receptor, TβRI. However, the latter did not correlate with conformational preference or activity. Hence, the difference in activity
arises from differences in their conformations, not their manner of receptor binding, suggesting that a matrix protein that
differentially binds them might determine their distinct activities.
Transforming growth factor beta isoforms, TGF-β1, -β2, and
-β3, are small (25 kDa) secreted homodimeric signaling
proteins. They coordinate wound healing, modulate immune
cell function, maintain the extracellular matrix, and regulate
epithelial and endothelial cell growth and differentiation.1 Their
importance is demonstrated by the many human diseases that
result from disruption or dysregulation of the TGF-β signaling
pathway, including developmental disorders, such as Marfan’s
disease,2 and adult diseases such as cancer3 and fibrosis.4
TGF-β isoforms signal through two surface receptors, known
as the TGF-β type I and type II receptors (TβRI and TβRII,
respectively). TGF-βs assemble TβRI and TβRII into a TβRI2-
TβRII2 heterotetramer in a sequential manner, first by binding
TβRII followed by recruitment of TβRI.5 The stepwise
assembly of TβRI and TβRII into a TβRI2-TβRII2 hetero-
tetramer is driven by binding of TβRI to a composite TGF-β/
TβRII interface.6,7 The assembly of the TβRI2-TβRII2
heterotetramer triggers a transphosphorylation cascade where-
by the constitutively active TβRII kinase phosphorylates TβRI
in a negative regulatory domain known as a GS box. This
activates the TβRI kinase, which phosphorylates cytoplasmic
effectors,8 including the canonical nuclear-translocating Smad
proteins,9 but others as well.10 The TGF-β type III receptor
(TβRIII), a cell surface proteoglycan with a short noncatalytic
cytoplasmic domain, binds all three TGF-β isoforms and
promotes the formation of the signaling complex with TβRI
and TβRII.11 The ability of TβRIII to potentiate assembly of
the signaling complex is especially important for TGF-β2 since
TGF-β2 binds TβRII weakly, and most cells are poorly
responsive to TGF-β2 in the absence of TβRIII.12
The TGF-β isoforms are encoded by distinct genes and are
highly conserved relative to one another and across species,
with the human TGF-β isoforms sharing between 71−79%
identity (Supporting Information, Figure S1A). The three-
dimensional structures of the TGF-βs are similar, consisting of
two cystine-knotted monomers tethered together by a disulfide
bond.13−16 The monomers are described as adopting the shape
of an extended hand, and the homodimer is formed by packing
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the palm of one hand into the heel of the other (Supporting
Information, Figure S1B).
TGF-β isoforms are indistinguishable in most cell-based
reporter gene and growth inhibition assays.17 The primary
exception is TGF-β2, which is 100−1000-fold less potent than
TGF-β1 and TGF-β3 in cell lines that lack TβRIII.12,18,19 The
TGF-β isoforms are nonetheless each required in vivo as the
isoform-specific null mice are inviable: TGF-β1 null mice have
an autoimmune-like inflammatory disease and die within a few
days of weaning,20,21 TGF-β2 null mice exhibit developmental
defects of the heart, spinal column, urogenital tract, eye, and
inner ear and die just before birth,22 and TGF-β3 null mice are
defective in lung development, have cleft palate, and die about a
day after birth.23 The phenotypic differences in the null mice
correlate with differences in tissue expression patterns. TGF-β1,
for example, is widely expressed in both developing embryos
and adults, consistent with the widespread multifocal
inflammatory disease characteristic of the TGF-β1 null mice,
while TGF-β2 and TGF-β3 are abundantly expressed in the
developing heart and lungs, consistent with major devel-
opmental defects of these organs in the corresponding null
mice.
Though the three-dimensional structures of the isoforms are
similar, intrinsic differences among them might also contribute
to the requirement of each in vivo. This was first suggested
when it was shown that TGF-β1 and TGF-β3 have opposing
effects in skin wound healing, with topical application of
purified TGF-β3 preventing and TGF-β1 promoting scarring.24
The mechanism in wound healing has recently been shown to
be due to differences in chemoregulated cell migration,25 with
TGF-β3 promoting epidermal cell migration, and TGF-β1
neither promoting nor inhibiting migration.26 The differences
between isoforms have been further suggested by tissue explant
studies in which cleft palates, excised from developing TGF-β3
null embryos, developed normally when exogenous purified
TGF-β3 was added to the culture medium, but not when TGF-
β1 or TGF-β2 was added27−29 and by gene replacement studies
where “knock-in” of the coding sequence for the mature
domain of TGF-β1 into the TGF-β3 locus, and vice versa, led
to partial, but not complete, rescue of the mutant
phenotype.30,31 These results indicate that there are indeed
intrinsic differences between isoforms that contribute to their
distinct functions in vivo.
The solution structure of TGF-β113 and the crystal structure
of TGF-β315 are similar: the palm α-helix, α3, packs into the
heel of the other monomer to form a compact “closed” dimer
(Supporting Information, Figure S1B). TGF-β1 and TGF-β3
nevertheless appear to differ in solution, as NMR secondary
shifts and {1H}-15N heteronuclear NOEs indicate that α3 is
well-ordered and rigid in TGF-β1,13 but not in TGF-β332,33
(Supporting Information, Figure S2). The disorder in the
region corresponding to α3 in TGF-β3 is also suggested by the
crystal structure of the TβRII/TGF-β3 complex, where the two
subunits are rotated away from one another by 101° in a
noncanonical “open” conformation and there is no electron
density for α3 (Figure 1A).34 Though it is conceivable that the
open form of TGF-β3 might be a consequence of either
differences in the solution conditions under which the NMR
studies were performed (TGF-β1 in 5% D2O at pH 4.2 and
TGF-β3 in 6% dioxane-d8, 2% methanol-d3, 87% H2O, and 5%
D2O at pH 2.9) or the low pH at which the TGF-β3/TβRII
complex was crystallized (pH 4.5), this is unlikely as TGF-β3
Figure 1. Closed and open forms of TGF-β3 and construct design for this study. (A) Closed and open conformations of TGF-β3. Closed form is
from the crystal structure of unbound TGF-β3 (PDB code 1TGJ), while the open form is from the crystal structure of the TGF-β3/TβRII complex
(PDB code 1KTZ; TβRII not displayed). Open form differs from the closed by a 101° degree rotation of the monomers away from one another; the
open form also has no electron density for the α-helix 3 and connecting loops (residues 55−72, dashed line). Disorder of α-helix 3 in the open form
is likely caused by steric overlap between residues near the C-terminal end of α-helix 3 and the heel of the opposing monomer; this is shown by the
structure below the “closed” form in which TGF-β3 monomers from the closed form (with an intact α-helix 3) have been overlaid onto the partial
monomer structures of the open form. Steric clashes between α3 and the heel of one monomer and the other are highlighted in green. (B) Amino
acid sequence alignment of TGF-β1 and -β3 and the sequences of TGF-β131, TGF-β313 and TGF-β3H4. Secondary structural elements correspond
to those from the crystal structure of TGF-β3 (PDB code 1TGJ). Residues from TGF-β1 are highlighted with a gray background, while those from
TGF-β3 with a blue background; the same color scheme is used for TGF-β131, TGF-β313, and TGF-β3H4. (C, D) Interaction of α-helix 3 of one
monomer with the heel of the other for the closed form of TGF-β1 and -β3 (PDB codes 1KLC and 1TGJ, respectively). Heel residues conserved
between TGF-β1 and -β3 (L28, I22, M104, V106, and A41) are highlighted in light and dark pink. Helical residues that differ between TGF-β1 and
-β3 are highlighted in red.
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alone was recently crystallized in the open form at neutral pH.35
The α-helix 3 region cannot be structurally ordered in the open
conformation since it would sterically overlap with residues in
the heel of the other monomer (Figure 1A). The overall
conclusion based on a synthesis of these observations is that in
solution TGF-β3 undergoes a conformational equilibrium
between the “closed” and “open” states, with the open state
predominating (KCO ≫ 1; Figure 1A). TGF-β1 may also
undergo a similar equilibrium, but with the closed state
predominating (KCO ≪ 1).
The difference in KCO between TGF-β1 and TGF-β3 might
be due to differences in packing interactions in the dimer
interface, with more favorable interactions favoring the closed
form. The differences in KCO might alternatively be due to
differences in the intrinsic stability of α-helix 3, with a more
stable helix more strongly resisting the transition from the
closed to open form (thus favoring the closed form). The
objective of this study was to investigate the underlying basis
for the differences in KCO between TGF-β1 and TGF-β3 and
whether this might underlie their differences in biological
activity.
■ EXPERIMENTAL PROCEDURES
Plasmid Constructs. The coding sequences for the mature
TGF-β3, TGF-β131, and TGF-β313 signaling ligands (each
336 nucleotides in length) were synthesized (Genscript). The
synthetic genes were inserted between the NdeI and HindIII
sites downstream of the T7 promoter in plasmid pET32a
(Novagen). The TGF-β3 A54L, H58Y, G63A, and T67Q
mutant, termed TGF-β3H4, was constructed by performing
site-directed mutagenesis (QuikChange Site-Directed Muta-
genesis kit, Stratagene) of the T7-based TGF-β3 construct
described above. The coding sequence for the mature domain
of TGF-β131 was also used to replace the corresponding
sequence for the mature domain of TGF-β1 in the CHO cell
expression vector pcDNA-GS-TGF-β1 (kindly provided by Dr.
Peter Sun, NIAID, Rockville, MD).36 The coding sequence for
TGF-β131 in this expression vector (designated pcDNA-GS-
TGF-β131) is preceded by the rat serum albumin leader
peptide and the TGF-β1 pro-domain, both of which are
required for the proper maturation and secretion of the mature
dimer into the culture medium.
Protein Preparation. TGF-β3, TGF-β313, and TGF-β3H4
were expressed in bacteria, refolded, and purified using the
procedure previously described for TGF-β3.37 TβRII-ED
(residues 15−130) and TβRI-ED (residues 7−91) were
expressed in bacteria, refolded, and purified as previously
described.38,39 TGF-β1 and TGF-β131 were expressed and
purified from conditioned medium produced by an over-
expressing stably transfected CHO cell line. The cell line used
to produce TGF-β1 has been previously described36 and was
kindly provided from Dr. Peter Sun (NIAID, Rockville, MD).
The TGF-β131 cell line was generated by transfecting the
pcDNA-GS-TGF-β131 construct into CHO-lec3.2.8.1 cells
using Lipofectamine 2000 (Invitrogen) following the same
protocol for TGF-β1.36 The highest expressing stable trans-
fected clone was selected by ELISA and chosen for large-scale
protein production as described.36 TGF-β1 and TGF-β131
were purified as described,36 but with the modification that ion-
exchange chromatography was used in the last step of the
purification in place of size exclusion chromatography. The ion-
exchange chromatography was performed by dialyzing the
TGF-β1 or TGF-β131 preparation into 0.1 M acetic acid and
loading onto a Source 15S cation exchange column (GE
Healthcare) previously equilibrated in ligand buffer (20 mM
sodium acetate, 30% isopropanol, pH 4.0). The column was
then washed with three column volumes of ligand buffer and
eluted with 200−600 mM linear NaCl gradient in ligand buffer
over 10 column volumes. The corresponding dimer peak was
pooled and dialyzed against 4 L of 100 mM acetic acid (4 h/
cycle, 3 cycles).
NMR Sample Preparation. Uniformly isotopically labeled
TGF-β313 and TGF-β3H4 used in the NMR studies were
obtained by growing transformed Escherichia coli BL21(DE3)
cells (EMD Biosciences) on M9 minimal medium enriched
with 0.1% (w/v) 15NHCl4 or 0.1% (w/v)
15NHCl4 and 0.3%
(w/v) uniformly 13C-labeled D-glucose (Cambridge Isotope
Laboratories) following the procedure described by Marley.40
Selectively isotopically labeled forms of TGF-β131 were
obtained by culturing CHO-lec3.2.8.1 cells stably transfected
with the pcDNA-GS-TGF-β131 construct in SFM4CHO serum
free medium (Hyclone) custom formulated so that it lacked
leucine, tyrosine, glycine, valine, and cysteine. The labeled
amino acids (Cambridge Isotope Laboratories) were added to
the medium according to the concentrations in its original
formulation. Four different selective labeling schemes, each
with one 15N-labeled amino acid and one 13CO labeled amino
acid, were used as shown in Table 2. NMR samples of TGF-
β313, TGF-β131, and TGF-β3H4 were prepared by buffer
exchanging the purified protein into 87% H2O, 5% D2O, 6%
dioxane-d8 and 2% methanol-d3 at pH 2.9. The buffer
exchanged protein samples, which had a concentration of
0.25−0.5 mM and a volume of 325 μL, were transferred to
clean Shigemi thinwall microcells (Shigemi).
NMR Spectroscopy. NMR data were collected at 40 °C
using a Bruker 700 MHz spectrometer equipped with a 5 mm
1H{13C,15N} z-gradient “TCI” cryogenically cooled probe
(Bruker Biospin). Backbone resonances of TGF-β313 and
TGF-β3H4 were assigned by recording and analyzing
HNCACB,41 CBCA(CO)NH,42 HNCO,43 HCACO,44 and
HBHACONH42 triple resonance data sets. NMR data were
processed and analyzed using the nmrPipe45 and Sparky46
software packages, respectively. Backbone amide 15N T1,
15N
T2, and {
1H}-15N NOE relaxation parameters were measured in
an interleaved manner at 40 °C at a 15N frequency of 70.95
MHz using 1H-detected pulse schemes previously described.47
The T1 and T2 data sets were each collected using 8−10 delay
times, varying between 16−3200 ms and 16−192 ms,
respectively. The T1 and T2 relaxation times were obtained
by fitting relative peak intensities as a function of T1 or T2 delay
time to a two-parameter decaying exponential. NOE values
were obtained by taking the ratio of peak intensities from
experiments performed with and without 1H presaturation and
by applying a correction factor to account for the incomplete
recovery of both 15N and 1H magnetization.48
Circular Dichroism Spectroscopy. CD measurements
were performed at 25 °C in the far UV (200−250 nm) on a
JASCO J-815 spectropolarimeter using quartz cells with a path
length of 1 mm. CD spectra were measured with 0.25 mg mL−1
TGF-β samples in 10 mM H3PO4 (pH 2.9) and were processed
by subtracting the buffer contribution. Experimental data were
expressed as mean residue ellipticity (degree × cm2/dmol).
Surface Plasmon Resonance (SPR) Binding Assays.
SPR binding studies were performed with a BIAcore 3000
instrument (GE Healthcare) and were analyzed using the
software package Scrubber2 (Biologic Software). TGF-βs were
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biotinylated and captured on carboxymethyl dextran (CM5)
chips. This was accomplished by adding a 1.25-fold excess of
the purified TβRI and TβRII ectodomains in 0.1 M NaHCO3
at pH 7.5 to TGF-β1, TGF-β3, TGF-β131, TGF-β313, and
TGF-β3H4 and then by adding 10 molar equivalents of sulfo-
NHS-LC-LC-Biotin (Pierce). Singly biotinylated TGF-βs were
separated from receptors and doubly and multiply biotinylated
forms by applying them to a Source S cation exchange column
(GE Healthcare) in the presence of 30% isopropanol at pH 4.0
and eluting with a linear 0−0.5 M NaCl gradient. Biotinylated
TGF-βs were captured by injecting them over a CM5 sensor
chip (GE Healthcare, Piscataway, NJ) to which 5000 RU
streptavidin had been covalently attached to all four flow cells
using an amine coupling kit (GE Healthcare). Surface densities
of captured TGF-βs were kept at 50−300 RU to minimize
rebinding artifacts. Binding assays were performed by injecting
2-fold serial dilutions of the receptors in duplicate or triplicate
in HBS-EP buffer (GE Healthcare) at a flow rate of 50 or 100
μL min−1 for kinetic experiments. Surfaces were regenerated by
a brief injection of 4 M guanidine hydrochloride (10 s contact
time at a flow rate of 100 μL min−1). Baseline correction was
performed by double referencing.49 Kinetic analyses were
performed by global fitting with a simple 1:1 model. Standard
errors were obtained from the variation in the fitted parameters.
Sandwich Assay for Quantifying Chemoregulated Cell
Migration. The chemoregulated migration assay was per-
formed as previously described.25 This was accomplished by
monitoring the migration of dermal fibroblasts from the center
of native collagen gels where the TGF-βs had been added at
concentrations of 1, 10, 100, and 1000 pg mL−1. The migration
of the fibroblasts was then quantified by counting the cells
along the length of the collagen-containing cylinder using a
digitally stepped microscope. The measurements for each TGF-
β at each concentration were performed in triplicate. The
experiment was repeated three times, and the reported values
are the mean from a single representative experiment; reported
errors correspond to the deviation among replicates.
■ RESULTS
Design and Production of TGF-β313 and TGF-β131.
The hypothesis of this study is that the difference in KCO is
mainly determined by intrinsic differences in the stability of α-
helix 3 and that the isoform-specific biological activities arise
from differences in KCO. This hypothesis is based on the
differences in the calculated helical propensity of α-helix 3,
which is nearly 10-fold higher for TGF-β1 compared to TGF-
β3 (Table 1). These calculations, which were performed using
the program Agadir,50,51 show that much but not all of the
difference in the helical stability is due to substitution of an α-
helix-stabilizing alanine at position 63 in TGF-β1 with an α-
helix-destabilizing glycine in TGF-β3 (Figure 1B). The
alternative explanation, that packing interactions between
monomers differ, seems unlikely since all of the residues in
the “heel” region against which α3 is packed are conserved
between TGF-β1 and TGF-β3 (Figure 1C,D). The residues
within α-helix 3 that interact with residues in the heel region
are also the same, except residue 58, which is a histidine in
TGF-β3 but a tyrosine in TGF-β1 (Figure 1C,D).
To investigate our hypothesis, two TGF-β chimeras were
generated in which residues 54−75 were swapped between
TGF-β1 and TGF-β3 (Figure 1B). The swapped region
corresponds to the region shown to be flexible in TGF-
β332,33,52 and includes α-helix 3 (residues 57−68) as well as
several flanking residues. There are nine amino acid differences
in the swapped region, including L54, Q57, Y58, K60, A63,
Q67, H68, G71, and A75 in TGF-β1 and A54, T57, H58, T60,
G63, T67, L68, E71, and S75 in TGF-β3. The expectation was
that the TGF-β1 variant with the α3 region from TGF-β3
(designated TGF-β131) would be altered such that the open
form was favored (KCO ≫ 1), while the TGF-β3 variant with
the α3 region from TGF-β1 (designated TGF-β313) would
favor the closed form (KCO ≪ 1). To generate the TGF-β131
and TGF-β313 chimeric proteins, the coding sequences of both
were synthesized and inserted into a T7-based expression
vector. TGF-β313 was obtained by expressing it in E. coli and
refolding and purifying it as described for TGF-β3.53 TGF-β131
was also expressed at a level comparable to that of TGF-β313 in
E. coli, but attempts to refold the denatured monomers into
native disulfide-linked dimers were unsuccessful. The parent
protein, TGF-β1, is similarly behaved, and therefore TGF-β131
was produced using the same CHO cell expression system
previously used to produce TGF-β1.36 TGF-β313 and TGF-
β131, as well as another variant described below designated
TGF-β3H4, were found to run as a single band at 25 kDa on
SDS gels under nonreducing conditions, but as a single band at
12.5 kDa under reducing conditions (Supporting Information,
Figure S3).
Backbone Amide Assignments. The 1H−15N HSQC
spectrum of TGF-β3 includes many intense signals in the
random coil region that arise from residue 54−75, which are
disordered.32 The 1H−15N HSQC spectrum of TGF-β313,
when recorded under identical conditions, 87% H2O, 5% D2O,
6% dioxane-d8, and 2% methanol-d3 at pH 2.9 and 40 °C, has
significantly improved spectral dispersion and much more
uniform signal intensities. These improved spectral features
enabled full assignment (102/102 expected non-proline
residues) of the backbone resonances of TGF-β313 using a
single 0.4 mM 15N, 13C sample and standard triple-resonance
experiments implemented on a 700 MHz spectrometer (Figure
2A).
TGF-β131 was expressed at a high level and could be readily
purified from the conditioned medium produced by the stably
transfected CHO cells, but it proved impractical to prepare an
Table 1. Sequences and Predicted Helix Propensity for
Peptides of α-Helix 3a
constructs sequences helical content (%)
TGF-β1 QYSKVLALYNQH 4.8
TGF-β1 Q57T TYSKVLALYNQH 5.1
TGF-β1 Y58H QHSKVLALYNQH 2.6
TGF-β1 K60T QYSTVLALYNQH 5.2
TGF-β1 A63G QYSKVLGLYNQH 0.9
TGF-β1 Q67T QYSKVLALYNTH 3.8
TGF-β1 H68L QYSKVLALYNQL 4.4
TGF-β1 Y58H, A63G, Q67T QHSKVLGLYNTH 0.4
TGF-β3 THSTVLGLYNTL 0.5
TGF-β3 T57Q QHSTVLGLYNTL 0.5
TGF-β3 H58Y TYSTVLGLYNTL 0.7
TGF-β3 T60K THSKVLGLYNTL 0.5
TGF-β3 G63A THSTVLALYNTL 2.5
TGF-β3 T67Q THSTVLGLYNQL 0.7
TGF-β3 L68H THSTVLGLYNTH 0.5
TGF-β3 H58Y, G63A, T67Q TYSTVLALYNQL 5.0
aCalculated using the program Agadir.50,51
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15N or 15N,13C uniformly labeled sample for assignment
purposes owing to the high cost of the culture medium.
Therefore, an alternative labeling strategy was adopted in which
residues in unique i−i+1 dipeptides were selectively labeled
with the corresponding 13CO-labeled amino acid at position i
and the corresponding 15N-labeled amino acid at position i+1.
This strategy is designed to enable definitive assignment of the
amide of residue i+1 by recording the 1H−15N plane of an
HNCO. This strategy was previously used to successfully assign
a number of residues in CHO-cell derived TGF-β1,54,55 but has
the disadvantage that unambiguous assignment of each amide
requires preparation of a separate sample. This limited the
number of amides that could be definitively assigned;
accordingly two judiciously chosen residues inside and outside
the swapped region (L62 and L64 and Y39 and L45,
respectively) were assigned. The residues inside the swapped
region corresponded to those that had {1H}-15N NOEs greater
than 0.75 (i.e., were rigid) in TGF-β1, but significantly less than
0.75 in TGF-β3 (i.e., were flexible), while those outside the
swapped region were chosen in regions that had {1H}-15N
NOEs greater than 0.75 (i.e., were rigid) in both TGF-β1 and
TGF-β3. The labeling schemes designed to assign Y39, L45,
L62, and L64 are listed in Table 2.
The 1H−15N HSQC of the Scheme 1 sample (13CO-Gly, 15N-
Tyr) exhibited 7−8 strong signals, while the 1H−15N HSQC
spectra of the Scheme 2, 3, and 4 samples (all of which were
labeled with 15N-Leu, but with a different 13CO-labeled amino
acid) each exhibited 11−12 strong signals. These spectra,
shown in black contours in Figure 2B,C, are largely consistent
with expectations based on the amino acid content of TGF-
β131, which contains 7 tyrosine and 10 leucine residues. The
corresponding 1H−15N planes of the HNCO spectra, in
contrast, exhibit either a single signal in the Scheme 1 sample
(Figure 2A, cyan contours) or one signal with a unique
chemical shift and one signal that has the same chemical shift in
the Scheme 2, 3, and 4 samples (Figure 2B, green, magenta, and
cyan contours, respectively). The single signal of the Scheme 1
sample and the unique signals of the Scheme 2, 3, and 4
samples are presumed to correspond to Y39, L45, L62, and
L64, respectively. The same signal present in each of the
Scheme 2, 3, and 4 samples has a very narrow line width and is
presumed to be L2, which lies near the N-terminus and is
highly flexible.
Flexibility and Conformational Preference Switched
for TGF-β313 and TGF-β131. The backbone amide {1H}-15N
NOEs were measured for both TGF-β313 and TGF-β131 at 40
°C on a Bruker 700 MHz spectrometer (Figure 3A, B). TGF-
β313 residues 59, 60, 63, 66, 67, and 68 in α-helix 3 all have
high NOE values (>0.75) (Figure 3A). This suggests that the α-
helix 3 of TGF-β313 is structurally ordered, which is similar to
TGF-β1, not TGF-β3 (Supporting Information, Figure S2).
TGF-β131 residues 62 and 64 in α-helix 3 region have low
NOE values (0.35 and 0.47 respectively), while residues Y39
and L45 have high NOE values (>0.75), indicating that the α-
helix 3 region of TGF-β131 is flexible. Thus, substitution of
residues 54−75 from TGF-β1 into TGF-β3 caused α3 to
become rigid, while substitution of residues 54−75 from TGF-
β3 into TGF-β1 caused α3 to become flexible.
The secondary structure of TGF-β313 was assessed by
analyzing the secondary shifts using the program PECAN,
which provide a sensitive and accurate indicator of secondary
Figure 2. Assigned 1H−15N HSQC spectra of TGF-β313 and TGF-β131. (A) Assigned HSQC of TGF-β313 with peaks labeled by their one letter
amino acid code and residue number. (B) 1H−15N HSQC of 15N-tyrosine selectively labeled TGF-β131 overlaid with the HN plane of HNCO data
for Scheme 1 (cyan) labeled TGF-β131. (C) 1H−15N HSQC of 15N-leucine selectively labeled TGF-β131 (black contours) overlaid with the HN
plane of an HNCO for Scheme 2 (green contours), Scheme 3 (magenta contours) and Scheme 4 (cyan contours) labeled TGF-β131. Peak labeled
with a green asterisk (*) was observed in the HN planes of all HNCO data.
Table 2. Selective Labeling Schemes for TGF-β131
scheme 13CO labeled 15N labeled unique dipeptide
1 Gly Tyr G38-Y39
2 Cys Leu C44-L45
3 Val Leu V61-L62
4 Gly Leu G63-L64
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structure propensities.56 This showed that α3 is highly probable
in TGF-β313 (Figure 3C). To directly confirm that α3 was
present in TGF-β313, we recorded a three-dimensional 15N-
edited NOESY spectrum and identified numerous dαN(i,i+3)
and αN(i,i+4) NOEs which are diagnostic for well-ordered α-
helices (Supporting Information, Figure S4). Thus, α3 is
structurally ordered in TGF-β313, which is similar to TGF-β1,
not TGF-β3.
TGF-β313, in addition to forming a stable α-helix 3, is also
expected to adopt the closed state, with α3 from one monomer
packing against the heel of the other monomer. To investigate
whether the stable α3 in TGF-β313 also promoted the
“closing” of the dimer, the assigned chemical shifts common
to TGF-β3 and TGF-β313 were compared (Figure 4A). This
showed that there were three regions with relative large
chemical shift perturbations centered about Ile22, Leu28, and
Tyr50. These residues were found to be either in the heel
region or in the prehelix loop, which in the closed form of
TGF-β3, directly interact with α3 (Figure 4B). This indicates
that the conformation of TGF-β313 differs from TGF-β3, most
likely because it adopts a closed conformation similar to TGF-
β1.
The backbone 15N T1 and T2 relaxation times for residues in
regions of regular secondary structure of TGF-β313 were found
to have mean values of 1116 ± 66 and 60.0 ± 7.0 ms,
respectively, when measured at a 15N frequency of 70.95 MHz.
These relaxation times correspond to an isotropic rotational
correlation time (τc) of 12.7 ns, which is very close to the 12.2
ns rotational correlation time of TGF-β1 deduced from
backbone 15N T1 and T2 relaxation times measured at 50.68
MHz (Supporting Information, Tables S1 and S2). The
correspondence of the correlation times for TGF-β313 with
those of TGF-β1 would be unexpected if the monomers were
not rigidly packed against one another as in TGF-β1, thereby
providing further evidence that TGF-β313 predominantly
adopts the closed form with the two monomers rigidly packed
against one another.
Flexibility and Conformational Preference Also
Switched for Helix-Stabilized TGF-β3 Variant, TGF-
β3H4. The data presented above clearly demonstrate that
swapping the region between residues 54−75 swaps the
flexibility and the position of the KCO equilibrium. The effect
of swapping residues 54−75 on KCO could be through an
increase in the intrinsic stability of α3, or alternatively through
alterations in interactions between residues in α-helix 3 and
residues in the heel region of the other monomer. Though it
was previously hypothesized that helical stability was the major
contributor to differences in KCO between TGF-β1 and TGF-
β3, this was not directly evaluated through the studies of the
two chimeras, TGF-β313 and TGF-β131. To evaluate this
more directly, a helix-stabilized variant of TGF-β3 was designed
that had just four amino acid substitutions relative to TGF-β3.
The substitutions include H58Y, G63A and T67Q within α3
and A54L outside α3. The H58, G63, and T67 residues of
TGF-β3 were selected for substitution since Agadir calculations
showed that these residues contribute the greatest to the helical
stability of α3 in TGF-β1 (Table 1). The Agadir calculations
further showed that simultaneous substitution of all three
residues increases the helical stability of α3 in TGF-β3 such
that it is comparable to that of TGF-β1 (Table 1). Two of the
substituted residues within α3 are expected to have no direct
contact with the opposing monomer A63 and Q67, while the
third substituted residue, H58 packs against the other monomer
with surface area of 117 Å2. The A54L substitution was selected
because L54 packs against A63 in TGF-β1 and may therefore
indirectly stabilize the helix.
The helix-stabilized TGF-β3 variant, TGF-β3H4, was
expressed, refolded, and purified using the same procedure as
TGF-β313. The 1H−15N HSQC spectrum of TGF-β3H4
showed highly dispersed peaks with uniform intensities. This
indicated that TGF-β3H4 likely adopts an ordered structure,
similar to TGF-β1 and TGF-β313. To examine this more
directly, a 15N,13C labeled TGF-β3H4 sample was prepared,
and its backbone resonances were assigned using standard
triple-resonance methodology (Figure 5A). To examine the
backbone flexibility, a 15N-labeled TGF-β3H4 sample was
prepared, and the backbone {1H}-15N NOEs were measured
(Figure 5B). The {1H}-15N NOE measurements showed that
TGF-β3H4 had a similar overall pattern as TGF-β313,
including T60, V61, A63, and Q67 within α3, which all had
high (>0.75) {1H}-15N NOE values. The analysis of secondary
structure propensities using the program PECAN further
showed there is a high probability for helix formation in the
α3 region (Figure 5C). Thus, TGF-β3H4 has a structurally
ordered α-helix 3 region, similar to TGF-β1 and TGF-β313.
TGF-β3H4 also appears to adopt the closed conformation as a
comparison of the assigned chemical shifts of TGF-β3H4 with
those of TGF-β3 identified the same three regions in the
comparison of TGF-β313 and TGF-β3 (Figure 4C,D).
Circular Dichroism Measurements. The TGF-β isoforms
have been previously analyzed by circular dichroism (CD)
Figure 3. NMR relaxation and secondary structure analysis of TGF-
β313 and TGF-β131. (A) {1H}-15N NOEs of TGF-β313. {1H}-15N
NOE values for residues 57, 58, 61 62, 64, and 65 in α-helix 3 region of
TGF-β313 could not be accurately measured due to peak overlap. (B)
{1H}-15N NOEs of residues Y39, L45, L62, and L64 in TGF-β131. (C)
Secondary structure probabilities of TGF-β313 calculated from NMR
secondary shifts by the program PECAN;56 positive and negative
values indicate α-helical and β-strand probabilities, respectively.
Secondary structure diagram shown along the top corresponds to
that of TGF-β1 (PDB 1KLC).
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under acidic conditions.57 These studies showed that the
measured helical content of TGF-β1 matched that calculated
from its three-dimensional structure, while that of TGF-β3 was
much lower than expected (at the time the only available
structure was the crystal structure of TGF-β3, which as noted,
adopts the closed form15). Thus, it should be possible to
complement the NMR measurements described above with CD
measurements. TGF-β1, TGF-β3, TGF-β313, TGF-β131, and
TGF-β3H4 were therefore analyzed by CD under conditions
comparable to that previously used in Pellaud’s study (10 mM
phosphoric acid, pH 2.9) (Figure 6). The CD spectrum of
TGF-β1 shows more negative ellipticity at 220 nm and more
positive elliptictiy at 200 nm compared to TGF-β3, consistent
with the NMR analysis that shows that TGF-β1 has greater
Figure 4. Chemical shift perturbation between TGF-β3 and TGF-β313 and TGF-β3 and TGF-β3H4. (A, C) Chemical shift perturbation between
TGF-β3 and TGF-β313 and TGF-β3 and TGF-β3H4, respectively. Plotted values correspond to the average chemical shift perturbation of 1H and
15N chemical shifts given by Δav = [(Δδ2NH + Δδ2N/25)/2]1/2 between corresponding residues. (B, D) Residues with the largest shift perturbations
between TGF-β3 and TGF-β313 and TGF-β3 and TGF-β3H4, respectively, mapped onto the crystal structure of TGF-β3 (PDB code 1TGJ).
Figure 5. Resonance assignment, {1H}-15N NOE measurements, and secondary structure analysis of TGF-β3H4. (A) Assigned 1H−15N HSQC of
TGF-β3H4. Assigned peaks are indicated by their one letter amino acid code and residue number. (B) {1H}-15N NOEs for TGF-β3H4. (C)
Secondary structure probabilities of TGF-β3H4 calculated from NMR secondary shifts by the program PECAN;56 positive and negative values
indicate α-helical and β-strand probabilities, respectively. Secondary structure diagram shown along the top corresponds to that of TGF-β1 (PDB
1KLC).
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helical content. The CD spectra of TGF-β313 and TGF-β3H4
were furthermore shown to be similar to that of TGF-β1, while
the TGF-β131 spectrum was shown to be similar to that of
TGF-β3. These results confirm the prior conclusions drawn
from the NMR studies: TGF-β1, TGF-β313, and TGF-β3H4
include a stable α3 and are predominantly closed, while TGF-
β3 and TGF-β131 include a disordered α3 and are
predominantly open. The similarity of the CD spectra for the
proteins in the two groups further suggest that the position of
the KCO equilibrium is also qualitatively similar; i.e., KCO for
TGF-β313 and TGF-β3H4 is similar to that of TGF-β1, and
KCO of TGF-β131 is similar to that TGF-β3.
Biological Activities. TGF-β1 and TGF-β3 are indistin-
guishable in most commonly used cell-culture assays to assess
TGF-β activity, such as growth inhibition or Smad phosphor-
ylation assays. TGF-β1 and TGF-β3 have however been shown
to be distinguishable in a chemoregulated migration assay in
three-dimensional collagen matrices, which is thought to
underlie their distinct functions in dermal wound healing.25
The assay is performed using a “sandwich” format in which
dermal fibroblasts are plated at the interface between an upper
and lower matrix compartment in the presence of an isotropic
distribution of test mitogen. The migration of the fibroblasts in
response to the different conditions is examined by quantifying
their disposition within the collagen matrix. TGF-β3 is active in
the sandwich assay, eliciting directional migration in response
to cytokine distribution, while TGF-β1 and TGF-β2 neither
promote nor inhibit directional migration. This assay was
performed using TGF-β131, TGF-β313, and TGF-β3H4,
together with TGF-β1 and TGF-β3 as controls (Figure 7).
The assay was repeated three times, and errors were calculated
by statistical analysis.25 TGF-β131 gained function in this assay
so that it induced migration similar to TGF-β3, while TGF-
β313 lost function and thus does not induce migration, similar
to TGF-β1. TGF-β3H4 had significantly diminished activity
compared to TGF-β3 and is similar, but not identical, to TGF-
β1 (Figure 7). These data show that the biological activity
correlates with KCO: TGF-β3 and TGF-β131 both favor the
open form (KCO ≫ 1) and potently induce migration, while
TGF-β1, TGF-β313, and TGF-β3H4 favor the closed form
(KCO ≪ 1) and have little to no ability to induce migration.
Receptor Binding Properties. TGF-β1 and TGF-β3 had
previously been characterized in terms of binding TβRII and
recruiting TβRI using SPR-based methods with immobilized
biotinylated TGF-βs.37,58 These measurements, while demon-
strating very overall similar affinities and kinetics, had shown
small differences in the dissociation rate for TβRI binding by
the TGF-β:TβRII complex. TGF-β1 and TGF-β3 have a similar
association rate for TβRI recruitment, but TGF-β3 has slower
dissociation rate and hence a slightly greater affinity.58 To
determine whether these small differences in TβRI binding
were caused by differences in KCO, SPR kinetic analysis was
performed with biotinylated TGF-β1, TGF-β3, TGF-β313,
TGF-β131, and TGF-β3H4. To minimize artifacts that might
arise from biotinylation, TGF-βs were each prebound to the
purified TβRI and TβRII ectodomains and then biotinylated.
The biotinylated TGF-βs were then isolated using high
resolution ion-exchange chromatography under denaturing
conditions, which not only enabled complete removal of the
receptors, but also separation of singly, doubly, and multiply
biotinylated forms. The singly biotinylated TGF-βs were then
captured onto a high density streptavidin surface. The
sensorgrams, along with the fitted kinetic traces, are shown in
Figure 8. The tabulated rate and dissociation constants are
presented in Table 3.
TGF-β313 and TGF-β131 are shown to retain the same
kinetics and affinity for binding TβRII as TGF-β3 and TGF-β1.
The small difference in TβRI recruitment by TGF-β1 and
TGF-β3 noted in the prior study is reversed: TGF-β131 has a
characteristically slow off-rate, which is similar to TGF-β3, and
TGF-β313 has a faster off-rate, similar to TGF-β1. TGF-β3H4
binds TβRII with the same kinetics and affinity as TGF-β3, but
its kinetics and affinity for recruiting TβRI are characteristic of
TGF-β3, not TGF-β1 (Figure 8E, Table 3). Thus, even though
TGF-β3H4 has a stable α-helix 3 and adopts the closed form,
this does not affect the kinetics of TβRI binding. Together,
these results show that the small difference in TβRI recruitment
is not correlated with the differences in KCO.
■ DISCUSSION
The unique phenotypes of the TGF-β isoform-specific null
mice are largely explained by differences in the expression
patterns of the isoforms, indicating that the diversification of
Figure 6. CD spectra of TGF-β1, TGF-β3, TGF-β131, TGF-β313, and
TGF-β3H4 in 10 mM H3PO4 at pH 2.9 and 25 °C.
Figure 7. Chemoregulated motogenic response of dermal fibroblasts
to TGF-β ligands in the sandwich migration assay. Measurements for
each TGF-β at each concentration were performed in triplicate. The
experiment was repeated three times, and the reported values are the
mean from a single representative experiment; reported errors
correspond to the standard deviation among replicates. Baseline
migration controls in the absence of ligands ranged from 1.3 to 2.0%
and is represented by the dashed horizontal lines.
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the TGF-β superfamily to include three closely related TGF-β
isoforms has largely been driven by advantages that arise from
differences in their spatial-temporal expression patterns.20−23
The expansion of functionality by duplicating genes to fine-tune
spatial-temporal expression, without altering the properties of
the ligands so that they can be distinguished by the signaling
receptors or other binding proteins, does impose the
fundamental limitation that the isoforms can only achieve
their distinct functions without overlap in their expression
patterns. Thus, there is some advantage for ligands of the
superfamily to be distinguished, either by the signaling
receptors or by other binding proteins that differentially
regulate access to the signaling receptors.
The objective of this study was to investigate whether the
previously reported differences in the equilibrium between the
closed and open monomer arrangements, KCO, was caused by
Figure 8. Quantitative SPR measurements of receptor binding properties with biotinylated TGF-βs. (A) Sensorgrams obtained as TβRII alone was
injected (left) or TβRI was injected in the presence of 4 μM TβRII (right) over a TGF-β1 surface. The traces shown (black) correspond to triplicate
measurements of a 2-fold serial dilution of the receptor over the concentration range shown. The orange curves correspond to global fits of each data
set to a 1:1 binding model. (B−E) Same SPR experiments as in A, except over TGF-β3, TGF-β131, TGF-β313, or TGF-β3H4 surfaces, respectively.
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differences in helical stability and whether the differences in
KCO might contribute to the unique requirement of TGF-β1
and TGF-β3 in vivo that has been previously suggested based
on gene replacement30,31 and other studies.24,26−29 The
construction of the chimeric proteins, in which the unstable
palm helix in TGF-β3 was swapped into TGF-β1 and the stable
palm helix in TGF-β1 was swapped into TGF-β3, and analysis
of these by NMR and CD, showed that swapping the helical
regions swapped their preferred conformation. TGF-β313 was
shown to adopt the closed conformation characteristic of TGF-
β1 (Figures 3−4, 6), while TGF-β131 was shown to adopt the
open conformation characteristic of TGF-β3 (Figures 3−6).
The migration of dermal fibroblasts through a matrix of native
collagen was shown to correlate with the preferred con-
formation of the ligand, with the predominantly closed ligands
lacking detectable chemoregulated migration activity, and the
open ligands possessing potent chemoregulated migration
activity (Figure 7).
The primary limitation of the chimeras is that it is not
possible to determine whether the altered properties
specifically the shifts in the KCO equilibrium or changes in
migrationwere a direct consequence of changes in the helical
stability or altered conformation, or whether the inclusion of
sequence from the other isoform affected the equilibrium and
migration through other mechanisms. This limitation was
addressed by generating another TGF-β3 variant, TGF-β3H4,
in which only four residues were substituted. The substitution
of these four residues was predicted to increase the helical
stability to a similar extent as the TGF-β313 chimera, but
because only four residues were substituted rather than nine,
this decreased the likelihood that these residues would alter
either the conformation or migration through other mecha-
nisms. Thus, the finding that TGF-β3H4 adopted the closed
conformation and lost most of its activity in the migration assay
provides strong, though not conclusive evidence, that the shift
in the KCO equilibrium toward the closed state is caused by an
increase in helical stability and that the activity in the migration
assay is specifically due to the open conformation. The finding
that the migration activity of TGF-β3H4 was not entirely
abolished might be because KCO is not as far shifted to the
closed form as that of the TGF-β313. This is not apparent from
either the TGF-β3H4 α3 secondary structure propensities or
magnitude of the TGF-β3H4−TGF-β3 shift perturbations,
which were indistinguishable from those of TGF-β313, but is
suggested by the {1H}-15N NOE data, which showed somewhat
increased flexibility in the prehelix loop (Figure 5b).
To investigate the underlying mechanistic basis by which the
alterations in the sequence and conformation of the TGF-βs
might alter activity, the binding properties of TGF-β313, TGF-
β131, and TGF-β3H4 for the signaling receptors, TβRI and
TβRII, were investigated using SPR. The previous SPR studies
performed in our laboratory showed that TGF-β1 and TGF-β3
bound TβRII with the same overall affinity and kinetics, but
had small differences in their ability to cooperate with TβRII to
bind and recruit TβRI.58 This, together with the accompanying
structures of TGF-β1 and TGF-β3 bound to the TβRI and
TβRII ectodomains (Supporting Information, Figure S3),
suggested that these differences were due to residues 51, 57,
and 60 within the TβRI binding interface, which differ between
TGF-β1 and TGF-β3.58
The SPR binding studies reported here showed that TGF-
β131 had a somewhat higher affinity for TβRI due to a
somewhat slower disassociation rate, while TGF-β313 has a
somewhat lower affinity for TβRI due to a somewhat faster
disassociation rate (Table 3). This change in TβRI binding by
TGF-β131 and TGF-β313 is consistent with the swap of
residues 57 and 60, although it is impossible to rule out that the
altered conformation might have also had an effect since the
change in TβRI binding also correlates with the change of
conformation. The SPR binding studies further showed that the
ability of TGF-β3H4 to bind and recruit TβRI was
indistinguishable from that of TGF-β3. The absence of an
effect on TβRI binding is consistent with the substitution of
none of the residues known to affect TβRI binding, but it is
inconsistent with the altered conformation, which was closed
for TGF-β3H4, but open for TGF-β3. The overall conclusion,
therefore, is that the small differences in the rate at which TβRI
disassociates is determined by whether the TGF-βs include the
residues previously shown to influence TβRI binding, not
whether they adopt the open or closed state.
This finding is perhaps not surprising as the TβRI- and
TβRII-bound forms of TGF-β1 and TGF-β3 have been shown
to both be closed,6,58 and the rate of dissociation is presumably
determined by the rate at which all of the stabilizing
interactions, including those between residues 51, 57, and 60
of TGF-β and TβRI mentioned above, are simultaneously
disrupted. The finding that the TβRI association kinetics do not
correlate with the conformation of the TGF-βs is somewhat
surprising given that some of the TGF-βs are predominantly
open and must undergo a transition to the closed form upon
binding TβRI (since the bound forms for TGF-β1 and TGF-β3
have been shown to be closed6,58). The fact that the association
rates do not correlate suggests that the kinetics of the open and
closing transition are likely fast compared to other steps
required for TβRI recruitment, which might well be the case
given that the TβRII N-terminus has previously been shown to
undergo a disorder-to-order transition as it binds TβRI.6,34,58
Table 3. Binding Constants for TGF-β Ligands to the Signaling Receptors
surface analyte buffer suppl kon (M
−1 s−1) koff (s
−1) Kd (μM) Rmax (RU)
TGF-β1 TβRII none 7.2(±0.4) × 105 0.121(±0.007) 0.17 ± 0.01 53.6 ± 4.3
TGF-β3 TβRII none 1.2(±0.1) × 106 0.199(±0.009) 0.17 ± 0.01 79.2 ± 4.0
TGF-β131 TβRII none 5.5(±0.1) × 105 0.124(±0.002) 0.22 ± 0.01 41.3 ± 1.0
TGF-β313 TβRII none 1.4(±0.1) × 106 0.171(±0.003) 0.13 ± 0.01 64.5 ± 3.2
TGF-β3H4 TβRII none 5.1(±0.2) × 105 0.083(±0.002) 0.16 ± 0.01 67.0 ± 3.2
TGF-β1 TβRI 4 μM TβRII 3.3(±0.1) × 104 7.6(±0.4)x × 0.24 ± 0.01 27.6 ± 1.4
TGF-β3 TβRI 4 μM TβRII 3.5(±0.1) × 104 1.2(±0.1) × 10−3 0.034 ± 0.002 59.3 ± 3.0
TGF-β131 TβRI 4 μM TβRII 5.2(±0.1) × 104 2.6(±0.1) × 10−3 0.051 ± 0.001 27.4 ± 1.4
TGF-β313 TβRI 4 μM TβRII 5.4(±0.1) × 104 5.1(±0.2) × 10−2 0.95 ± 0.04 56.5 ± 2.9
TGF-β3H4 TβRI 4 μM TβRII 4.0(±0.1) × 104 1.9(±0.4) × 10−3 0.047 ± 0.003 56.4 ± 3.0
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This leads us to conclude that the differential effect of the
TGF-βs in the migration assay is due to differential interactions
with other TGF-β binding proteins that might be present.
These differential interactions could be mediated by the overall
conformational differences between the TGF-βs, or alter-
natively through direct recognition of the substituted amino
acid residues. There is at present insufficient data to distinguish
these mechanisms, but it is nevertheless tempting to speculate
that it is the former, not the latter, as the opening and closing of
TGF-β results in a very large overall change in conformation
that has a high potential to be differentially recognized, either
structurally or as a result of differences in charge or
hydrophobicity.
There are several TGF-β binding proteins known, including
membrane-bound nonsignaling receptors, such the type III
receptor, or soluble proteins, such as the shed form of the type
III receptor, α2-macroglobulin, or decorin. These proteins
could be derived from the relatively low levels of calf serum
(1%) that were added to the collagen gels or proteins that are
secreted or shed by the dermal fibroblasts. The majority of
TGF-β binding proteins preferentially bind one isoform over
the others. TGF-β2 binds the soluble type III receptor, for
example, with an affinity that is roughly 3-fold greater than
TGF-β1 and 4-fold greater than TGF-β3.49 Both α2-macro-
globulin and decorin preferentially bind TGF-β1 and TGF-
β2.59,60 Hence, α2-macroglobulin and decorin might bind TGF-
β3 more transiently compared to TGF-β1, which in turn could
increase the rate at which TGF-β3 diffuses through the collagen
gels compared to TGF-β1. Collagen isoforms have not been
reported to bind TGF-βs, but if they do have a slight propensity
to interact, this could lead to the observed differences in the
migration assay, as TGF-βs that are closed or open might have
a differing propensity to interact with collagen thus affecting
their diffusion through the collagen matrix. Abundant decorin
and collagen is present in the epidermis; thus it seems plausible
that the TGF-βs are differentially interacting with these
molecules, as opposed to the soluble type III receptor or α2-
macroglubin, which are mainly present in serum.
The results present here have shown that residues within
helix 3 determine whether TGF-βs adopt the open or closed
state and that the open or closed state is likely responsible for
the differential activity of TGF-β1 and TGF-β3, as least as it
relates to signaling activity in the epidermis. The fact that
intrinsic differences among the isoforms do contribute to their
unique activities most likely reflects an added adaptation that
has enabled the TGF-βs to take upon their unique and
distinctive functions in vivo.
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